Adoptive T cell therapy of solid cancers

Keith L Knutson, Wolfgang Wagner, Mary L. Disis

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The development of immune-based approaches for the treatment of cancer has been actively investigated for many years. One strategy that has emerged as a potentially effective strategy for the treatment of aggressive established malignancies is adoptive T cell therapy. The power of this approach has been repeatedly observed in preclinical animal models. However, moving from homogeneous animal models to the heterogeneous human clinical setting has been very difficult. It is only in recent times that we have been able to pinpoint the problems of the clinical translation of adoptive T cell therapy. Some of the major problems are sources of tumor-specific T cells, ex vivo expansion, persistence, and anti-tumor activity. This review overviews the nature of these problems and some of the emerging solutions.

Original languageEnglish (US)
Pages (from-to)96-103
Number of pages8
JournalCancer Immunology, Immunotherapy
Volume55
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Cell- and Tissue-Based Therapy
T-Lymphocytes
Neoplasms
Animal Models
Therapeutics

Keywords

  • Adoptive T cell therapy
  • Antibody therapy
  • Cytokine therapy
  • Tumor immunology
  • Vaccines

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Adoptive T cell therapy of solid cancers. / Knutson, Keith L; Wagner, Wolfgang; Disis, Mary L.

In: Cancer Immunology, Immunotherapy, Vol. 55, No. 1, 01.2006, p. 96-103.

Research output: Contribution to journalArticle

Knutson, Keith L ; Wagner, Wolfgang ; Disis, Mary L. / Adoptive T cell therapy of solid cancers. In: Cancer Immunology, Immunotherapy. 2006 ; Vol. 55, No. 1. pp. 96-103.
@article{649c4ad5024b47ff992e1262cbb4bd03,
title = "Adoptive T cell therapy of solid cancers",
abstract = "The development of immune-based approaches for the treatment of cancer has been actively investigated for many years. One strategy that has emerged as a potentially effective strategy for the treatment of aggressive established malignancies is adoptive T cell therapy. The power of this approach has been repeatedly observed in preclinical animal models. However, moving from homogeneous animal models to the heterogeneous human clinical setting has been very difficult. It is only in recent times that we have been able to pinpoint the problems of the clinical translation of adoptive T cell therapy. Some of the major problems are sources of tumor-specific T cells, ex vivo expansion, persistence, and anti-tumor activity. This review overviews the nature of these problems and some of the emerging solutions.",
keywords = "Adoptive T cell therapy, Antibody therapy, Cytokine therapy, Tumor immunology, Vaccines",
author = "Knutson, {Keith L} and Wolfgang Wagner and Disis, {Mary L.}",
year = "2006",
month = "1",
doi = "10.1007/s00262-005-0706-1",
language = "English (US)",
volume = "55",
pages = "96--103",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - Adoptive T cell therapy of solid cancers

AU - Knutson, Keith L

AU - Wagner, Wolfgang

AU - Disis, Mary L.

PY - 2006/1

Y1 - 2006/1

N2 - The development of immune-based approaches for the treatment of cancer has been actively investigated for many years. One strategy that has emerged as a potentially effective strategy for the treatment of aggressive established malignancies is adoptive T cell therapy. The power of this approach has been repeatedly observed in preclinical animal models. However, moving from homogeneous animal models to the heterogeneous human clinical setting has been very difficult. It is only in recent times that we have been able to pinpoint the problems of the clinical translation of adoptive T cell therapy. Some of the major problems are sources of tumor-specific T cells, ex vivo expansion, persistence, and anti-tumor activity. This review overviews the nature of these problems and some of the emerging solutions.

AB - The development of immune-based approaches for the treatment of cancer has been actively investigated for many years. One strategy that has emerged as a potentially effective strategy for the treatment of aggressive established malignancies is adoptive T cell therapy. The power of this approach has been repeatedly observed in preclinical animal models. However, moving from homogeneous animal models to the heterogeneous human clinical setting has been very difficult. It is only in recent times that we have been able to pinpoint the problems of the clinical translation of adoptive T cell therapy. Some of the major problems are sources of tumor-specific T cells, ex vivo expansion, persistence, and anti-tumor activity. This review overviews the nature of these problems and some of the emerging solutions.

KW - Adoptive T cell therapy

KW - Antibody therapy

KW - Cytokine therapy

KW - Tumor immunology

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=28944452018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28944452018&partnerID=8YFLogxK

U2 - 10.1007/s00262-005-0706-1

DO - 10.1007/s00262-005-0706-1

M3 - Article

C2 - 15891880

AN - SCOPUS:28944452018

VL - 55

SP - 96

EP - 103

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 1

ER -